好酸球増加症候群：開発中の薬剤

好酸球増加症候群(HES)は、はっきりとした原因がなく、6ヶ月以上継続して末梢血中の成熟した好酸球数が1500個/μlを超え、好酸球の浸潤により心臓や神経系、骨髄などに障害が起きる疾患です。HESは、クローン性好酸球増加症（白血病など）および反応性好酸球増加症（感染症や自己免疫疾患、アトピー、副腎機能低下症、熱帯性好酸球増加症、癌など）を除外した後の、除外診断です。

当レポートでは、好酸球増加症候群治療薬の開発状況について調査しており、パイプライン製品の概要、治験段階別の製品概要、主要企業および薬剤のプロファイル、パイプライン製品の最新動向、および最新ニュース／プレスリリースなどを提供しています。

イントロダクション

• 調査範囲

好酸球増加症候群の概要

治療薬の開発

• パイプライン製品の概要
• 企業別のパイプライン
• 企業で開発中の製品

治療薬の評価

• 標的別
• 作用機序別
• 投与経路別
• 分子タイプ別

好酸球増加症候群の治療薬開発に従事している企業

• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Knopp Biosciences LLC
• 協和発酵キリン
• Stemline Therapeutics, Inc.

好酸球増加症候群：治療薬の評価

• 単剤製品
• 標的別
• 作用機序別
• 投与経路別
• 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

• 主なニュースとプレスリリース

付録

List of Tables

List of Tables

• Number of Products under Development for Hypereosinophilic Syndrome, 2021
• Number of Products under Development by Companies, 2021
• Products under Development by Companies, 2021
• Number of Products by Stage and Target, 2021
• Number of Products by Stage and Mechanism of Action, 2021
• Number of Products by Stage and Route of Administration, 2021
• Number of Products by Stage and Molecule Type, 2021
• Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
• Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, 2021
• Hypereosinophilic Syndrome - Pipeline by Incyte Corp, 2021
• Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, 2021
• Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, 2021
• Hypereosinophilic Syndrome - Pipeline by Nexeos Bio, 2021
• Hypereosinophilic Syndrome - Dormant Projects, 2021

List of Figures

List of Figures

• Number of Products under Development for Hypereosinophilic Syndrome, 2021
• Number of Products under Development by Companies, 2021
• Number of Products by Top 10 Targets, 2021
• Number of Products by Stage and Top 10 Targets, 2021
• Number of Products by Mechanism of Actions, 2021
• Number of Products by Stage and Mechanism of Actions, 2021
• Number of Products by Routes of Administration, 2021
• Number of Products by Stage and Routes of Administration, 2021
• Number of Products by Molecule Types, 2021
• Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2021, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 1 respectively.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

Reasons to Buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

• Introduction
• Hypereosinophilic Syndrome - Overview
• Hypereosinophilic Syndrome - Therapeutics Development
• Hypereosinophilic Syndrome - Therapeutics Assessment
• Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
• Hypereosinophilic Syndrome - Drug Profiles
• Hypereosinophilic Syndrome - Dormant Projects
• Hypereosinophilic Syndrome - Discontinued Products
• Hypereosinophilic Syndrome - Product Development Milestones
• Appendix